Global News

Oncodesign, KU Leuven, Ipsen collaborate on advancing drug discovery in Parkinson's disease

Wednesday, December 19, 2012 11:11 AM

Oncodesign, a biotech based in France, and the Laboratory for Neurobiology and Gene Therapy (LNGT) at the Katholieke Universiteit Leuven, have entered into a research collaboration to evaluate, along with a global specialty-driven pharmaceutical company Ipsen, Oncodesign’s compounds in multiple pharmacology models for Parkinson's disease.

More... »

New company NeRRe Therapeutics created to develop neurokinin antagonists from GSK

Wednesday, December 19, 2012 10:42 AM

NeRRe Therapeutics, a new drug discovery company, has been launched to develop a portfolio of clinical and pre-clinical neurokinin receptor antagonists divested from GlaxoSmithKline (GSK).

More... »

Arrowhead, Shire ink agreement to develop peptide-targeted therapeutics

Wednesday, December 19, 2012 09:41 AM

Arrowhead Research, a clinical stage targeted therapeutics company, has signed a research collaboration and license agreement with Shire, a specialty biopharmaceutical company, to develop and commercialize targeted peptide-drug conjugates (PDCs) by utilizing Arrowhead's human-derived Homing Peptide platform and Shire's therapeutic payloads.

More... »

Sutro, Celgene to develop next-gen ADCs and bispecific antibodies

Wednesday, December 19, 2012 09:14 AM

Sutro Biopharma, a San Francisco-based biopharmaceutical company, has formed a collaboration with Celgene, a multinational biopharmaceutical company, to design and develop novel antibody drug conjugates (ADCs) and bispecific antibodies for two undisclosed targets and to manufacture a proprietary Celgene antibody.

More... »

Teva signs new $3B syndicated revolving credit facility

Tuesday, December 18, 2012 02:23 PM

Teva Pharmaceutical Industries, a global pharmaceutical company, has entered into a new five-year, $3 billion unsecured revolving credit facility, which replaces its existing $2.5 billion credit facility.

More... »

Bio-Rad to acquire MorphoSys's research & diagnostics antibody business

Tuesday, December 18, 2012 09:16 AM

MorphoSys, a German biotech focused on human antibodies, has agreed to sell its research and diagnostic antibody segment AbD Serotec to Bio-Rad Laboratories, a multinational manufacturer and distributor of life science research and clinical diagnostic products.

More... »

Charlie Morris appointed to Almac’s clinical technologies executive team

Monday, December 17, 2012 04:01 PM

The Almac Group’s clinical technologies business unit has appointed Charlie Morris as vice president of new products and services. In this role, Morris will oversee the development of Almac’s IXRS technology and enhance the company’s metrics-based discipline to the software development process.

More... »

Phenex, Janssen form research collaboration on autoimmune, inflammatory disorders

Monday, December 17, 2012 02:09 PM

Phenex Pharmaceuticals, a privately held drug discovery and development company based in Germany, has entered into an agreement with Janssen Biotech and its affiliates to jointly discover compounds that target the nuclear hormone receptor RORγT and may have utility in the treatment of chronic autoimmune and inflammatory disorders including rheumatoid arthritis, psoriasis and inflammatory bowel disease.

More... »

UMCG initiates enrollment in RENEW trial for severe emphysema

Monday, December 17, 2012 12:31 PM

The University Medical Center Groningen has enrolled and treated the first patients in the FDA-approved RENEW pivotal trial to evaluate the RePneu Lung Volume Reduction Coil (LVRC) in severe emphysema. 

More... »

Catalent, UMN Pharma collaborate on biosimilar development, production in Japan

Monday, December 17, 2012 11:35 AM

Catalent Pharma Solutions, a Somerset, N.J.-based developer of solutions and drug delivery technology, has signed an agreement to provide UMN Pharma, a Japanese pharmaceutical company, a broad range of biosimilar cell lines using Catalent's proprietary GPEx technology.

More... »